Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant pleural mesothelioma: staging systems.

P Van Schil1

  • 1Department of Thoracic and Vascular Surgery, University Hospital of Antwerp, Wilrijkstraat 10, B-2650 Edegem, Antwerp, Belgium. paul.van.schil@uza.be

Lung Cancer (Amsterdam, Netherlands)
|June 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Intrathymic parathyroid adenoma presenting with seizures.

Acta chirurgica Belgica·2013
Same author

Endarterectomy combined with retrograde stenting for tandem lesions of the carotid artery.

Acta chirurgica Belgica·2011
Same author

Spontaneous pneumothorax: remaining controversies.

Minerva chirurgica·2011
Same author

Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification.

The European respiratory journal·2011
Same author

Restaging the mediastinum in non-small cell lung cancer after induction therapy: non-invasive versus invasive procedures.

Acta chirurgica Belgica·2011

Estimating malignant pleural mesothelioma tumor volume and spread is challenging. Modified Response Evaluation Criteria in Solid Tumors (RECIST) offer the most accurate method for assessing treatment response.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Radiology

Background:

  • Malignant pleural mesothelioma exhibits complex invasion patterns, complicating accurate staging.
  • Tumor volume estimation and local extension assessment are difficult due to the specific growth of mesothelioma.
  • Current staging systems for mesothelioma present challenges in precise evaluation.

Purpose of the Study:

  • To discuss widely used staging systems for malignant pleural mesothelioma.
  • To highlight the difficulties in restaging mesothelioma after induction therapy.
  • To present the modified Response Evaluation Criteria in Solid Tumors (RECIST) as the most accurate method for response evaluation.

Main Methods:

  • Review of existing staging systems for malignant pleural mesothelioma.

Related Experiment Videos

  • Discussion of challenges in restaging mesothelioma post-induction therapy.
  • Evaluation of the modified RECIST criteria for response assessment.

    • Main Results:

    • Existing staging systems for malignant pleural mesothelioma have limitations.
    • Restaging mesothelioma after induction therapy remains a complex and controversial issue.
    • The modified RECIST criteria demonstrate high accuracy in evaluating treatment response.

    Conclusions:

    • Accurate staging of malignant pleural mesothelioma is hindered by its invasive growth pattern.
    • The modified RECIST criteria provide the most reliable method for assessing treatment response in mesothelioma.
    • Further refinement in mesothelioma staging and response evaluation is warranted.